Queensland Centre for Gynaecological Cancer
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Queensland Centre for Gynaecological Cancer sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Queensland Centre for Gynaecological Cancer: 2 sponsored US clinical trials, 1 recruiting.
Queensland Centre for Gynaecological Cancer sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Endometrial Cancer Stage I, with 1 trials.
Mid-pack sponsor footprint
Queensland Centre for Gynaecological Cancer is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
Where Queensland Centre for Gynaecological Cancer enrollment is open (later-stage tilt)
1 recruiting of 2 indexed (50% open); 1 completed (50%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Endometrial Cancer Stage I (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Queensland Centre for Gynaecological Cancer: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Queensland Centre for Gynaecological Cancer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Queensland Centre for Gynaecological Cancer page
2 registered trials is a research-attention snapshot, not an endorsement of Queensland Centre for Gynaecological Cancer or any single study.
- 1 of Queensland Centre for Gynaecological Cancer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Endometrial Cancer Stage I is the condition Queensland Centre for Gynaecological Cancer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Endometrial Cancer Stage I trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Queensland Centre for Gynaecological Cancer pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.